Regencell Bioscience Holdings Ltd
Company Information
Industry Medicinal Chemicals & Botanical Products
SIC Code 2833
Entity Type other
SEC Category Non-accelerated filerEmerging growth company
State of Incorporation Cayman Islands
Country China
Business Address 11/F FIRST COMMERCIAL BUILDING, HONG KONG, ,
Mailing Address 11/F FIRST COMMERCIAL BUILDING, HONG KONG, ,
Phone 852 2155 0823
EIN 000000000
Financial Overview
FY2025
-$3.58M
Net Income
$8.44M
Total Assets
$-0.72
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | February 13, 2026 | View on SEC |
| 20-F Foreign company annual report | October 31, 2025 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | July 11, 2025 | View on SEC |
| 6-K Foreign company current report | June 30, 2025 | View on SEC |
| 6-K Foreign company current report | June 30, 2025 | View on SEC |
| 6-K Foreign company current report | June 17, 2025 | View on SEC |
| 6-K Foreign company current report | June 2, 2025 | View on SEC |
Annual Reports
20-F October 31, 2025
- Positive early results for ADHD treatment in clinical trials
- Asian sales grew 20% (core market)
Related Companies
Companies in the same industry (SIC: 2833)
Charlie's Holdings, Inc.
CHUC Medicinal Chemicals & Botanical Products
Canopy Growth Corp
CGC Medicinal Chemicals & Botanical Products
biote Corp.
BTMD Medicinal Chemicals & Botanical Products
Bon Natural Life Ltd
BON Medicinal Chemicals & Botanical Products
Medikra Inc.
MDKR Medicinal Chemicals & Botanical Products
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.